3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
Long-term follow-up from the EMPEROR-Preserved trial reveals durable empagliflozin benefits in HFpEF, emerging safety patterns, and unanswered questions about SGLT2 inhibitor therapy beyond the original 26-month median observation.
A detailed breakdown of pre-specified and post-hoc subgroup analyses from the EMPEROR-Preserved trial of empagliflozin in HFpEF, examining which patient populations saw the greatest and smallest benefit.
Plain-English breakdown of the EMPEROR-Preserved trial showing empagliflozin reduced CV death and heart failure hospitalization by 21% in patients with HFpEF.